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ABSTRACT 
Objective: To investigate the chemo-preventive effect of subcutaneous injection of bovine lactofericin (LfcinB) against 7, 12 dimethylbenz (a) 
anthracene (DMBA) induced carcinogenesis in swiss albino female mice. 
Methods: 30 animals were divided into 3 groups. 200μl of DMBA (0.025μg/μl) per animal three times per week as topical was used to induce skin 
cancer in both groups II and III. In addition to DMBA, group III was protected with subcutaneous injection of LfcinB (20μg/μl) while group I served 
as control. At the end of 16th
Results: Topical application of 200μl DMBA (0.025μg/μl) per animal three times per week has produced 100% tumor incidence in DMBA treated 
group at the end of 16
 week lysates/blood/serum were subjected to various tests such as antioxidant, glucose, liver enzymes and kidney 
marker parameters. 
th
Conclusion: LfcinB exerts its chemoprotective effect through acting as an antioxidant, thereby inhibiting carcinogenesis, hepatocellular and renal 
damage. Lfcin B may act as a promising chemoprotective agent against DMBA induced skin cancer. 
 week whereas only 20% developed tumors in the LfcinB+DMBA treated group. Antioxidants level were found to be 
significantly (P<0.01) depleted in reduced glutathione (GSH), glutathione reductase (GR), glutathione peroxidase (GPx), catalase (CAT) and liver 
enzymes, Alaninine aminotransferase (ALT) and Alkaline phosphatase (ALP). Subcutaneous administration of 200μl of LfcinB (20μg/μl) 
significantly (P<0.01) normalized the antioxidants (GSH, GR, GPx and CAT) levels. 
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INTRODUCTION 
Chemoprevention is a pharmacological process that involves the use 
of natural or synthetic product(s) to prevent, suppress, reverse or 
delay carcinogenesis [1]. The methods of possible chemoprevention 
include neutralization or detoxification of carcinogens, suppression 
of cell proliferation, induction of cell death, modulation of the 
immune system, suppression of genetic instability or mutation [2]. 
Many antioxidants have the capacity to inhibit cellular event 
associated with stages of carcinogenesis [3]. Chemoprevention may 
involve inhibition of various steps in tumor initiation, promotion 
and progression. Several potential mechanisms have been described 
and attempts have been made to classify agents broadly according to 
the effects they have on different stages of carcinogenesis. 
Compounds that inhibit cancer initiation are traditionally termed as 
“blocking agents”. They may act by preventing the interaction 
between chemical carcinogens or endogenous free radicals and DNA, 
thereby reducing the level of damage and resulting mutations which 
contribute not only to cancer initiation but also progressive genomic 
instability and overall neoplastic transformation [4]. Protection may 
be achieved as a consequence of decreased cellular uptake and 
metabolic activation of procarcinogens and/or enhanced 
detoxification of reactive electrophiles and free radical scavenging, 
as well as induction of repair pathways [5]. Other protective 
processes include modulation of DNA methyltransferases to prevent 
or reverse the hyper methylation-induced inactivation of tumor 
suppressor genes. Inhibition of histone deacetylases has also been 
described among a variety of effects of blocking agents on epigenetic 
mechanisms of carcinogenesis [6]. 
Bovine lactoferricin (Lfcin B) is a peptide fragment of bovine 
produced from lactoferrin (LF), a peptide obtained from cow’s milk 
by acid-pepsin hydrolysis of the lactoferrin [7]. Lfcin B consists of 
about 17 to 41 amino acid residues near to the NH2 end of bovine 
lactoferrin and has quite high proportion lop-sided group of basic 
amino acid residues. Lfcin is generated from the LF by gastric pepsin 
or by proteases in vivo. The extensive antimicrobial action of LF and 
LfcinB against microorganisms such as bacteria, fungi, parasites and 
viruses has been well documented. LF possess various antimicrobial 
properties which primarily acts by the chelation of iron. LF can bind 
to lipopolysaccharide (LPS) and DNA through an deficient iron 
mechanism. It has been proposed that a fragment of LF i.e. Lfcin B 
can cross the bacterial cell membrane resulting in the pushing of 
intact LF inside cytoplasm [8]. The intact LF or its proteases digest 
Lfcin B; it may then bind DNA and interfere with RNA synthesis. 
Considerable levels of LfcinB are established in the human stomach 
after intake of bovine lactoferrin, indicating that Lfcin B broken 
down naturally by means of proteases from cow’s milk [8]. 
Due to its well established antimicrobial action, considerable 
attention has been paid to LfcinB [9-11]. Recent in vivo studies have 
shown LfcinB as a potent anticancer agent [12-13]. LfcinB 
suppresses azoxymethane-induced colon cancer up to 83% when 
given orally to rats. A similar result was also obtained by oral 
administration of intact bovine lactoferrin, which increases the 
chances that LfcinB resulting from nutritional bovine lactoferrin 
may protect against colon carcinogenesis. Consumption of milk and 
milk products has been recently identified to reduced risk of 
colorectal cancer in humans [14] and at the same time reduced 
tumor growth in mice induced by 1, 2 dimethylhydrazines [15].  
Skin cancer is the most common form of cancer occurring in humans 
and proceeds through three distinct phases, initiation, promotion 
and progression. Skin cancer usually occurs more than that of lung, 
breasts, colorectal and prostate cancer; it is usually the most 
frequently diagnosed form of cancer. Skin cancer starts as 
precancerous lesions and environmental carcinogens play has been 
shown to play a role in the initiation of skin carcinogenesis [16, 17]. 
It represents the main and growing health problem in the public and 
of all new cancers diagnosed annually in the world, almost one-third 
was estimated to originate in the skin [18]. In the United States, 
almost 1.2 million new skin cancer cases are diagnosed each year 
[19]. The highest incidence of skin cancers were reported every year 
in South Africa and Australia than any other countries throughout 
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the world, due to the fact that populations of these countries receive 
high amounts of UV radiation [20, 21]. In India, skin cancer accounts 
for 1-2% of all cancers [22].  
DMBA is a potent carcinogen and a polycyclic aromatic hydrocarbon 
(PAH) consisting of four aromatic rings structure [23]. Dihydrodiol 
epoxide is the active metabolite that is produced during the 
metabolic activation of DMBA and is responsible for DNA damage. 
Reactive oxygen species (ROS) generated in excess during metabolic 
activation of DMBA also contributes to the oxidative stress and the 
DNA damage. It is generally used to initiate and promote skin 
carcinogenesis in Swiss albino mice [24, 25]. The fact that DMBA 
induces carcinogenesis urges us to find chemopreventive agents 
either of natural or synthetic origin for therapy using experimental 
animals [26]. Oxidative stress takes place in the cells due to 
unbalance in oxidant and antioxidant status of the cells. Oxidative 
stress causes damaged to DNA, lipids and proteins and as well 
impair the structure and function of membrane bilayer [27]. 
Reactive oxygen species (ROS) mediated lipid peroxidation has been 
shown to be involved in causing many cancers including skin cancer. 
Mammalian cells have a number of antioxidant defense mechanisms 
that neutralizes the harmful effects of ROS and protect the cells. In 
spite of the role played by the skin antioxidants in maintaining the 
redox potential of the cell, premature aging of skin and tumor 
initiation occurs if ROS are excessively generated in the skin [28, 
29]. In our previous research, we have demonstrated that Lfcin B 
inhibits GSTP1 activity in human placental and MDA-MB-231 cells, 
which may induce synergistic effects when used in combination with 
antineoplastic drugs that are substrates of GSTP1 enzyme. This 
combination will exert a double attack on cancers overexpressing 
GSTP1, first sensitizing them to anticancer drugs by preventing their 
metabolism and secondly by suppressing the GSTP1 sensitizing cells 
to anticancer drugs which are either substrates of GSTP1 or inducing 
programmed cell death by activating c-Jun N-terminal kinases (JNK) 
[30]. In our current study, we have investigated the in vivo 
chemopreventive activity of Lfcin B in DMBA induced mouse model 
of skin cancer. This type of role of Lfcin B as the chemopreventive 
agent has never been conducted before.  
MATERIALS AND METHODS 
Chemicals 
7, 12-dimethylbenz (a) anthracene (DMBA) was purchased from 
Sigma-Aldrich India, Reduced glutathione was obtained from 
Calbiochem, India, 1-chloro-2, 4-dinitrobenzene (CDNB), 5,5’ dithio 
(bis) nitro benzoic acid (DTNB), thiobarbituric acid (TBA), and 
trichloroacetic acid (TCA) were purchase from Himedia India. AST, 
ALP, ALT, Uric acid, Urea and Creatinine kits were purchased from 
Span diagnostic limited (Surat) India.  
Female, Swiss Albino mice 5-8 w old, weighing 20-35g were 
purchased from Luvas, Haryana, India. The animals were maintained 
in the Central Animal House, Sharda University. The animals were 
housed in polypropylene cages and provided standard pellet diet 
and water ad libitum and maintained under controlled conditions of 
temperature and humidity, with a 12 h light/dark cycle. The project 
was approved by the institutional animal ethics committee (Register 
number 1173/PO/Ere/S/08/CPCSE). The animals were maintained 
as per the principles and guidelines of the ethical committee for 
animal care of Sharda University in accordance with Indian National 
Law on animal care and use.  
Experimental design 
The animals were randomly assorted into the following groups:  
Group I (n=10); this group receive a normal diet and were treated 
with 200 µl of acetone on the skin thrice a week and serve a negative 
control 
Group II (n=10); this group of animals received a normal diet and 
were treated thrice a week with 200 µl of DMBA only. This group 
serves as positive control. 
Group III (n=10); this group also receive a normal diet and were 
treated thrice a week with 200 µl of DMBA topically along with 200 
µl of lactoferricin B subcutaneously. This group serves as a test. 
Experimental duration and animal sacrifice 
The experiment was conducted for 16 w. At the end of the 
experiment, all the animals were sacrificed by cervical dislocation 
and blood was collected by heart puncture and centrifuged for 
glucose, AST, ALT and ALP estimations while tissues (liver and 
kidneys) were removed for various tests (reduce glutathione (GSH), 
catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase 
(SOD) and lipid peroxides (LPO). 
Preparation of tissue homogenate 
Liver and kidneys were carefully excised from the animals, washed 
in a phosphate buffer saline (PBS) and weighed. Homogenate of the 
tissues was made in 100 mM Tris-HCl buffer (pH 7.4) and was used 
for the estimations of reduce glutathione (GSH), glutathione S-
tranferase (GST), catalase (CAT), glutathione peroxidase (GPx), and 
superoxide dismutase (SOD) and lipid peroxidation (LPO). 
Reduced glutathione (GSH)  
Estimations of anti-Oxidants and xenobiotic enzymes activities 
GSH was estimated by the method described by Ellman [31]. About 
500μl of tissue homogenate was precipitated with 2000μl of 5% 
trichloroacetic acid (TCA) and then centrifugation. 1000μl of the 
supernatant was taken out and added 500μl ml of 5, 5’ dithio (bis) 
nitrobenzoic acid (19.8 mg of 5, 5’ dithio (bis) nitrobenzoic acid in 
100 ml of 1% sodium citrate) and 3000μl of phosphate buffer. The 
yellow color developed was read at 412 nm. 
Glutathione-S-transferase (GST) 
The activity of GST was measured by the method prescribed by Habig et 
al., [32]. The reaction mixture containing 1000μl of the buffer, 100μl of 1-
chloro-2, 4-dinitrobenzene (CDNB), 100μl of homogenate and 1700μl of 
distilled water was incubated at 37 °C for 5 min. The reaction was 
started on the addition of 1000μl of glutathione. The increase in 
absorbance was followed for 3 min at 340 nm.  
Estimation of catalase (CAT) 
Estimation of CAT was determined by the method described by 
Takahara et al., [33]. Tissue homogenate (200μl) was mixed with 
1200μl of 50 mM phosphate buffer pH 7.0. The reaction was 
initiated by the addition of 1000μl of 30 mM H2O2 solution. The 
decrease in absorbance was recorded at 240 nm after 30 seconds 
intervals for 3 min by a spectrophotometer. The enzyme activity was 
expressed as μ moles of H2O2
Estimation of superoxide dismutase (SOD) 
 decomposed/min/mg protein. 
The activity of SOD was measured by the method of Misra and Fridovich 
[34]. Tissue homogenate (100μl) was mixed with ethanol (750μl) and 
chilled chloroform (150μl) and were centrifuged. To supernatant 
(500μl) equal amount of 0.6 mM EDTA solution and 1 ml of 0.1 M 
carbonate-bicarbonate (pH 10.2) buffer. The reaction was initiated by 
the addition of 500μl of 1.8 mM epinephrine (freshly prepared) and the 
increase in absorbance at 480 nm was measured in a 
spectrophotometer. One unit of the SOD activity was the amount of 
protein required to give 50% inhibition of epinephrine auto-oxidation. 
Estimation of lipid peroxidation (LPO) 
The homogenate was utilized for the determination of lipid 
peroxidation by the method described by Ohkawa et al., [35]. 
Released Malondialdehyde (MDA) was used as the record for lipid 
peroxidation. In short, to 200μl of tissue homogenate, 200μl of 8.1% 
SDS, 1.5 ml of 20% acidic corrosive and 1500μl of 0.8% 
thiobarbituric acid (TBA) were included. The volume was made up 
to 4000μl with distilled water and was incubated in a water bath at 
95.5 °C for 60 min. The above solution was then cooled and 100μl of 
water and 5000μl of n-butanol/pyridine blend were included and 
shaken vigorously. The constituents were centrifuged and the 
organic layer was isolated for estimation of absorbance at 532 nm. 
Estimation of glutathione peroxidase (GPx) 
GPx activity was measured by the method described by Rotruck et 
al., [36]. To 0.2 ml of buffer, 0.2 ml of EDTA, 0.1 ml of sodium azide 
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and 0.5 ml of tissue homogenate were included. Glutathione solution 
(0.2 ml) and hydrogen peroxide (0.1 ml) were included the mixture. 
The contents were blended well and were incubated at 37 °C for 10 
min alongside the control tubes containing all the reagents, 
however, no enzyme. Following 10 min, the reaction was inhibited 
by the addition of 0.4 ml of 10% TCA. Tissue homogenate (0.2 ml) 
was added to the control tubes. The tubes were centrifuged and the 
supernatant was examined for glutathione content at 340 nm by the 
addition of Ellman's reagent. 
Estimation of glutathione reductase (GR) 
Glutathione reductase was evaluated by the method depicted by 
Carlberg and Mannervik [37]. The total reaction volume contained 1 
ml of 0.2M sodium phosphate buffer (PH= 7.0), 2 mM EDTA, 1 mM 
EDTA, 0.2 mM NADPH. The reaction was initiated by including 25μl 
of the homogenate (cytosol). The decrease in absorbance is 
measured after for 3 min at 340 nm. The decrease in absorbance is 
directly proportional to the activity of the enzyme. 
Total protein  
Estimations of biochemical parameters 
Total protein was estimated method described by Lowry et al., [38] 
using bovine serum albumin as standard. 
Blood glucose estimation 
Blood glucose was estimated by using glucose oxidase end point 
assay using a commercial kit (Span diagnostics Ltd, India) according 
to the manufacturer’s protocol based on Trinder 1969 [39]. Table 1 
shows the procedure for estimation of blood glucose. 
 
Table 1: Procedure for estimation of blood glucose 
Pipette into tube marked Blank Standard Test 
Plasma/serum - - 10μl 
Reagent 3 - 10μl - 
Working reagent glucose 1000μl 1000μl 1000μl 
 
Calculation 
Serum/plasma glucose (mg/dl) = (absorbance of test/absorbance of 
standard) X 100 
Estimation of aspartate aminotransferase (AST) 
Aspartate aminotransferase activity was estimated by modified UV 
(IFCC), a kinetic assay using a commercial kit (Span diagnostics Ltd, 
India) according to the protocol provided by the manufacturers as 
recommended Schumann et al., [40]. Table 2 shows the procedure 
for estimation of aspartate aminotransferase. 
Calculation 
AST activity = ΔA/minute × Kinetic factor 
Where kinetic factor, 1768 
Estimation of Alanine aminotransferase (ALT) 
ALT modified UV (IFCC), the kinetic assay was performed using a 
commercial kit (Span diagnostics Ltd, India) according to 
manufacturer’s protocol as recommended Schumann et al., [41] 
table 3. Shows the procedure for estimation of alanine 
aminotransferase. 
 
Table 2: Procedure for estimation of aspartate aminotransferase 
Pipette into tube marked  Test 
Serum/plasma 100μl 
Working AST reagent 1000μl 
 
Table 3: Procedure for estimation of alanine aminotransferase 
Pipette into tube marked Test 
Serum/plasma 100μl 
Working ALT reagent 1000 μl 
 
Calculation 
ALT activity = ΔA/minute × Kinetic factor 
Where kinetic factor, 1768 
Estimation of alkaline phosphatase 
Alkaline Phosphatase is estimated by pNPP-AMP (IFCC), a kinetic 
assay using a commercial kit (Span diagnostics Ltd, India) 
according to the protocol provided by the manufacturers as by 
Tietz et al., [42] table 4 shows the procedure for estimation of 
alkaline phosphatase. 
Calculation 
ALP activity = ΔA/minute × Kinetic factor 
Where kinetic factor, 2712 
Statistical analysis  
The experimental results obtained are expressed as mean±standard 
deviation (SD). The data was subjected to one-way analysis of variance 
(ANOVA) and differences between samples were determined by Tukey 
multiple comparison tests using the SPSS 22 (Statistical program for 
Social Sciences) program. The level of significance was set at p<0.01. 
  
Table 4: Procedure for estimation of alkaline phosphatase 
Pipette into marked tube Test 
Serum/plasma 20μl 
Working ALP reagent 1000μl 
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The results of the study indicate that LfcinB possesses 
chemoprotective effect. Administration of DMBA has produced 
100% tumor incidence in DMBA treated group at the end of 16th
 
 
week whereas only 20% developed tumors in the LfcinB+DMBA 
treated group. The size of the tumors of the LfcinB+DMBA 
treated group was found to be significantly (P<0.01) decreased 
than those treated by DMBA only. The tumor volume of DMBA 
alone was found to significantly (P<0.01) higher than those 
LfcinB+DMBA treated group. A significantly decreased (P<0.001) 
in both liver and kidneys weight in DMBA treated animals was 
also noted. (table 5) shows initial and final weight of 
experimental animals. 
Table 5: Weight parameters of experimental animals 
Groups Body weight (g) Weight of liver (g) Weight of kidneys (g) 
Initial Final 
Control 31.825±2.22 32.70±1.25a 1.61±0.15a 0.60±0.07a a 
DMBA only 31.81±1.75 29.50±2.78a 1.49±0.26b 0.49±0.07b 
DMBA+LfcinB 
b 
31.81±1.75 32.70±1.41a 1.60±0.36a 0.59±0.12a a 
 
Values are expressed as mean±SD (n=10). Values that are not 
sharing common superscript in the same column differ significantly 
at p<0.01. Group 1(control) was compared against treated groups: 
Group II (DMBA alone) and Group III (LfcinB+DMBA) "The 
superscript “a” and “b” denotes statistical significance. For example, 
if groups I, II and III have “a” it means there is no statistical 
significance between them at p<0.01. On the other hand, if group I 
has "a" and either groups II, III have "b" it means there is statistical 
significance between them at p<0.01. 
Administration of DMBA has produces 100% tumor incidence in 
DMBA treated group at the end of 16th
Tumor volume was measured using the formula v =4/3π [D1/2] 
[D2/2] [D3/2] where D1, D2 and D3 are the three diameters of the 
tumors (cm). "The superscript “a” and “b” denotes statistical 
significance. For example, if group I and II both has “a” it means 
there is no statistical significance between them at p<0.01. On the 
other hand, if group I has "a" and group II has "b" it means there is 
statistical significance between them at p<0.01. Tumor burden was 
calculated by multiplying tumor volume and the number of 
tumors/animal. Number in parenthesis indicated a total number of 
animals bearing tumors. 
 week while only 20% 
developed tumors in the LfcinB+DMBA treated group. The size of the 
tumors on the LfcinB+DMBA treated group was found to be 
significantly (P<0.01) reduced than those treated by DMBA only 
(table 6). The tumor volume of DMBA alone was found to 
significantly (P<0.01) higher than those LfcinB+DMBA treated 
group. The tumor burden and a total number of the tumor were also 
found to be higher in DMBA alone than the LfcinB treated group. 
This has clearly indicated the effect of the LfcinB on the both tumor 
size and tumor volume in addition to its chemoprotective benefits. 
Analysis of liver enzymes (AST, ALT ALP) has indicated that the 
group treated with DMBA alone exhibit elevated liver enzymes 
compared with control, and LfcinB+DMBA treated groups. 
Although there was no significant change observed in AST 
between DMBA and LfcinB+DMBA, there was a significant change 
in ALT and ALP in DMBA alone as compared to the control and 
LfcinB+DMBA.  
Total protein was also found to be depleted. Liver is the major organ 
involved in detoxification of xenobiotics. Activation of pro-
carcinogens like the DMBA also takes place in the liver. It is 
important that the liver function be tested to ascertain whether the 
action the DMBA causes changes in the liver enzymes. It is also 
important to check the effect of LfcinB on the liver enzymes. The 
results of the liver function tests are presented in table 7. 
  
Table 6: Effect of Lfcin B on tumor incidence, tumor size, and tumor volume and tumor burden in DMBA treated mice 
Groups Tumor incidence Tumor size(cm) Tumor volume (cm3 Tumor burden(cm) 3 Total number of tumors ) 
DMBA only 100% (10/10) 0.60±0.37 0.36±0.40a 3.43±4.16a 7.70±3.89a a 
LfcinB+DMBA 20% (2/10) 0.12±0.15 0.004±0.005b 0.005±0.007b 0.50±0.71b b 
 
Table 7: Hepatic marker enzymes 
Groups AST (UI/l) ALT (UI/l) ALP (UI/l) Total protein (μg/ml) 
Control 80.46±7.90 40.12±2.22a 61.78±5.17a 465.44±68.17a a 
DMBA alone 91.68±8.04 58.80±3.84b 81.76±9.69b 437.10±100.30b 
DMBA+LfcinB 
b 
82.88±9.14 42.39±3.89a/b 64.42±9.64a 458.85±22.39a a/b 
Values are expressed as mean±SD (n=10). Values that are not sharing common superscript in the same column differ significantly at p<0.01. Group 
1(control) was compared against treated groups: Group II (DMBA alone) and Group III (LfcinB+DMBA) "The superscript “a” and “b” denotes 
statistical significance. For example, if groups I, II and III have “a” it means there is no statistical significance between them at p<0.01. On the other 
hand, if the group I has "a" and either groups II, III have "b" it means there is statistical significance between them at p<0.01. 
 
At P<0.01 GSH was found to be significantly decreased in the group 
treated with DMBA only. A significant difference in the level of GSH 
has been observed between DMBA alone and other groups (control 
and LfcinB+DMBA). GST was also found to decrease in LfcinB treated 
group and DMBA alone treated group. This implies that GST is 
expressed in cancer-bearing mice compare to control, and 
LfcinB+DMBA treated groups. Glutathione peroxidase was also 
found to be decreased in DMBA alone treated groups. A significant 
difference was also observed in glutathione peroxidase content 
between the group treated with DMBA alone and other groups. In a 
similar manner, glutathione reductase and catalase were also found 
to differ between the groups. A significant difference was note in the 
level of catalase and glutathione reductase between DMBA and other 
groups while no differences were observed between LfcinB+DMBA 
and the control. Lipid peroxidation was found to be higher in the 
group treated with DMBA than other groups. Total protein content 
was also found to be depleted. The results of hepatic oxidative 
markers are presented in table 8. 
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Values are expressed as mean±SD (n=10). Values that are not sharing common superscript in the same column differ significantly at p<0.01. Group 
1(control) was compared against treated groups: Group II (DMBA alone) and Group III (LfcinB+DMBA) "The superscript “a” and “b” denotes 
statistical significance. For example, if groups I, II and III have “a” it means there is no statistical significance between them at p<0.01. On the other 
hand, if the group I has "a" and either groups II, III have "b" it means there is statistical significance between them at p<0.01. 
 
Renal GSH was found to be significantly depleted at p<0.01 in the 
group treated with DMBA only then in the other groups. However, 
no significant differences were observed between control and 
LfcinB+DMBA treated groups. At P<0.01, GST was also found to be 
significantly different in the group treated with DMBA alone than in 
the other groups. No significant difference was observed between 
control and DMBA alone treated group. In a similar situation, 
glutathione peroxidase, catalase and superoxide dismutase were 
found to be significantly depleted at P<0.01. A significant difference 
was observed in the level of glutathione peroxidase, catalase and 
superoxide dismutase between DMBA alone and the other groups 
(control and LfcinB+DMBA). The lipid peroxidation was also high in 
animals treated with DMBA alone. At P<0.01, significant different 
exist between DMBA alone and the other groups.  
However, no significant differences exist between LfcinB+DMBA 
group and the control. The renal oxidative stress and xenobiotic 
enzymes are presented in table 9. 
 

















































































































Values are expressed as mean±SD (n=10). Values that are not sharing common superscript in the same column differ significantly at p<0.01. Group 
1(control) was compared against treated groups: Group II (DMBA alone) and Group III (LfcinB+DMBA) "The superscript “a” and “b” denotes 
statistical significance. For example, if groups I, II and III have “a” it means there is no statistical significance between them at p<0.01. On the other 
hand, if the group I has "a" and either groups II, III have "b" it means there is statistical significance between them at p<0.01. 
 
Administration of 200μl of LfcinB subcutaneously has 
significantly lowered the blood glucose in group III compared to 
control group and DMBA alone treated groups. A significant 
changes has been observed in all the experimental groups at 
P<0.01. High glucose level was obtained in group II and differs 
significantly (P<0.01) than in all other groups. The decreased in 
blood glucose level associated with subcutaneous administration 
of LfcinB indicates the potential anti-diabetic abilities of bovine 
lactoferricin. The effect of administration of LfcinB is presented 
in table 10. 
 
Table 10: Effect of administration of LfcinB on blood glucose 






Values are expressed as mean±SD (n=10). Values that are not sharing common superscript in the same column differ significantly at p<0.01. Group 
1(control) was compared against treated groups: Group II (DMBA alone) and Group III (LfcinB+DMBA) "The superscript “a”, “b” and “c” denotes 
statistical significance. For example, if group I and II both has “a” it means there is no statistical significance between them at p<0.01. On the other 
hand, if group I has "a" and group II has "b" and group III has “c” it means there is statistical significance between them at p<0.01 
 
The result of this study shows that the pro-carcinogen DMBA 
depleted the concentration of GSH while increasing the activity of 
GST. The activity of hepatic marker enzymes (AST, ALT and ALP) 
was found to have increased in DMBA treated animals significantly 
(P<0.01). This may be due to the activation of DMBA from pro-
carcinogen to carcinogen followed by concomitant toxic to the liver. 
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The toxicity of DMBA has been confirmed by a significant depletion 
of GSH (P<0.01) in kidney and liver of DMBA treated animals 
compared with the control and LfcinB treated groups. The 
antioxidant status (GSH, GR, GPx, CAT and SOD) were also found to 
be depleted in group II. However subcutaneous injecting of 200μl of 
LfcinB three time per week for 16 w have significantly (P<0.01) 
increases the level of this antioxidants thereby preventing and 
reducing the tumor volume as well as the tumor size. This has 
clearly indicated the antioxidant benefits of LfcinB and its 
chemoprotective role in carcinogenesis. 
Cancer chemoprevention as a strategy makes use of natural or 
synthetic products to prevent, delay, inhibitor reversed the 
development of cancer caused by a variety of agents. 
Chemoprotection has emerged as a means of cancer prevention for 
both individual under high risk and the general population. The 
potential role of cancer chemoprevention has been confirmed by 
several epidemiological and experimental studies [43] which 
emphasized the importance of the chemoprevention in both pre-
neoplasm and neoplasm individuals. Molecules capable of acting as 
an antioxidant and Antioxidant enzymes as well has a potential role 
in providing protection against oxidative damage due to generated 
ROS as a result of DMBA treatment. Total protein was found to be 
decreased due to the free radical generated by DMBA in liver and 
kidney of DMBA treated mice. On the other hand, total protein in 
LfcinB treated group was found to be almost same with control 
animals indicating the carcinogenic reversal effect. DMBA may exert 
it inhibitory in protein synthesis, through reduced transcription of 
RNA and translation of DNA. It was described that the carcinogen, 
DMBA upsets intracellular calcium balance, thereby damaging 
endoplasmic reticulum which result in depletion of the protein [44]. 
GSH is a water-soluble antioxidant that plays a critical role in 
protecting the cell against oxidative damage and highly reactive 
oxygen species [45]. It makes a significant amount (about 90%) of 
the total non-protein in most cells and also plays an important role 
in detoxification of xenobiotics and peroxides into neutral or less 
toxic compounds through the catalysis by glutathione-s-transferase 
and glutathione peroxidase [46, 47]. The tripeptide participated in 
other cellular reactions, like the glyoxylase system, reduction 
reaction of ribonucleotides into corresponding deoxyribo-
nucleotides, protein regulation and expression of gene through 
disulfide exchange reactions participates in the metabolism of 
estrogens, leukotrienes and prostaglandins, maturation of iron-
sulfur clusters of diverse proteins and in the operation of certain 
transcription factors [48]. The tripeptide is present in the cells 
either as a reduced (GSH) or oxidized (GSSG) form. Keeping a 
balanced ratio between reduced and oxidized form of GSH is 
important to the cell survival and depletion of GSH increases the risk 
of cell for oxidative damage [49]. Its presence is a pre-requisite for 
protection against oxidative stress. Depletion of GSH has been 
associated with many pathophysiological processes and generates 
ROS and oxidative stress which affect the integrity of the cell and 
membranes of the organelles. The antioxidant effect of LfcinB has 
manifested in group III as LfcinB tries to restore the depleted GSH 
provoked by DMBA treatment. The low level of antioxidants (GSH, 
CAT, SOD, GPx, and GR) indicates poor antioxidant status. Studies 
have reported the decreased in antioxidant enzymes (CAT and SOD) 
in squamous and papilloma carcinogenesis which leads to a pro-
antioxidant state of the cells, enabling tumorigenesis [50]. 
Oxidative stress leads to generation of MDA in the biological system. 
The MDA formed react with proteins and nucleic acid is thereby 
introducing cross linkages between nucleic acids and proteins, 
which result in changes in transcription and replication leading to 
the formation of tumors [51]. Elevated levels of MDA were observed 
in both kidney and liver of DMBA treated animals. Research has 
reported increased level of lipid peroxidation in the mouse skin 
model, which was decrease in response of flavonoids [52]. 
Significant decreased in MDA levels by LfcinB show reduce oxidative 
stress thus indicating it chemoprotective role against skin 
carcinogenesis. Oxidative stress causes injury to cells, induces gene 
mutation, and is involved in carcinogenesis by influencing 
intracellular signal transduction and transcription factors directly or 
indirectly via antioxidants. Oxidative stress is an indication of the 
imbalanced system between oxidants and antioxidant defenses. It 
occurs when oxidants overpower the antioxidant defense system 
and it is linked to many pathophysiologies including cancer [53]. 
GST is phase II detoxification enzymes which catalyzes the conjugation of 
reduced glutathione (GSH) with a variety of xenobiotics. The enzyme 
participates in detoxification reactions by catalyzing the conjugation of 
many electrophilic and hydrophobic compounds with reduced 
glutathione. In this study, GST was found to be significantly higher 
(P<0.01) in group II indicating that GST has been expressed in the 
cancer-bearing mice. Group III was found to have significantly (P<0.01) 
lower GST than in the other Groups indicating that LfcinB inhibits GST. 
An increased expression of GST pi has been reported in cancers of the 
breast, bladder, pancreas, colon, stomach, lung, neck and head, cervix, 
ovary, and, as well as soft tissue sarcoma, testicular embryonal 
carcinoma, glioma and meningioma [54-62]. In this scenario LfcinB has 
the ability of both acting as antitumor and inhibitor of GST found to be 
expressed higher in neoplasm cells than in normal cells. 
Glutathione peroxidase is one of the essential antioxidant defense 
systems protecting the cells against oxidative stress. The glutathione 
peroxides reduce hydroperoxides by utilizing reduced glutathione 
(GSH). It carries out the reduction of hydroperoxides and hydrogen 
peroxide using GSH. The present study found significantly (P<0.01) 
reduction in glutathione peroxidase in Group II compared with the 
other groups. This clearly indicates poor antioxidants status in 
DMBA treated animal due to the generation of reactive oxygen 
species. However, no difference was observed between control and 
LfcinB treated group (group III). In this respect, LfcinB has clearly 
reversed the carcinogenic effect thereby restoring the antioxidants 
back to normal. Glutathione reductase is an important enzyme 
involved in the recycle of oxidized glutathione to reduced 
glutathione. The enzyme catalyzes NADPH-dependent reduction of 
oxidized glutathione to reduce glutathione thereby maintaining the 
concentration of reduced glutathione. The study found that the 
cancer-bearing mice have significant decreased (P<0.01) in the level 
of glutathione reductase. The decreased in the level of glutathione 
reductase implies that oxidized glutathione could not be converted 
into reduced glutathione. This exposes the DMBA treated mice to 
oxidative stress and as a result free radical mediated oxidative stress 
cause structural and functional abnormalities in the cells, making 
them susceptible to carcinogenesis [63]. Aminotransferases are a 
group of enzymes which carries out biotransformation of amino 
acids from α-amino acids to oxo acids. The enzymes are confined 
within the liver and are not a normal component of plasma. Their 
function outside organ of origin is unknown [64, 65]. The largest 
pool of ALT is found in the cytosol of hepatic parenchyma cells. AST 
is present in cytosol and mitochondria of the liver cells and also 
available in cardiac muscle, skeletal muscle, pancreas and kidney 
[66]. ALT is used for specifically to determine the hepatocellular 
damaged [67]. Although AST is being used to assess the liver 
function, it is considered to be as an indicator for mitochondrial 
damaged particularly centrilobular regions of the liver [68] ALP are 
a family of enzymes that hydrolyzed phosphate esters at alkaline pH 
and are used as markers for cholestasis liver functions [69]. 
CONCLUSION 
The results from this study indicates that LfcinB exert it 
anticarcinogenic, chemoprotective effect through acting as an 
antioxidant thereby inhibiting carcinogenesis, hepatocellular and 
renocellular damage. 
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